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ABSTRACT: In the SPRINT (Systolic Blood Pressure Intervention Trial), the number of strokes did not differ significantly by
treatment group. However, stroke subtypes have heterogeneous causes that could respond differently to intensive blood
pressure control. SPRINT participants (N=9361) were randomized to target systolic blood pressures of <120 mm Hg
(intensive treatment) compared with <140 mm Hg (standard treatment). We compared incident hemorrhage, cardiac
embolism, large- and small-vessel infarctions across treatment arms. Participants randomized to the intensive arm had
mean systolic blood pressures of 121.4 mm Hg in the intensive arm (N=4678) and 136.2 mm Hg in the standard arm
(N=4683) at one year. Sixty-nine strokes occurred in the intensive arm and 78 in the standard arm when SPRINT was
stopped. The breakdown of stroke subtypes across treatment arms included hemorrhagic (intensive treatment, n=6, standard
treatment, n=7) and ischemic stroke subtypes (large artery atherosclerosis: intensive treatment n=11, standard treatment,
n=13; cardiac embolism: intensive treatment n=11, standard treatment n=15; small artery occlusion: intensive treatment
n=8, standard treatment n=8; other ischemic stroke: intensive treatment n=3, standard treatment n=1). Fewer strokes
occurred among participants without prior cardiovascular disease in the intensive (n=43) than the standard arm (n=61),
but the difference did not reach predefined statistical significance level of 0.05 (P=0.09). The interaction between baseline
cardiovascular risk factor status and treatment arm on stroke risk did not reach significance (P=0.05). Similar numbers of
stroke subtypes occurred in the intensive BP control and standard control arms of SPRINT. (Hypertension. 2021;77:1391-1398.
DOI: 10.1161/HYPERTENSIONAHA.120.16027.)
Key Words: atherosclerosis ◼ blood pressure ◼ hemorrhagic stroke ◼ hypertension ◼ ischemic stroke

S

troke is the fifth leading cause of death in the United
States and the leading cause of adult disability.
The estimated annual cost of stroke is expected
to increase by $240 billion by 2030.1 The most recent
American Heart Association/American Stroke Association statement on the primary prevention of stroke
states, “The relationship between blood pressure (BP)
and stroke risk is strong, continuous, graded, consistent,
independent, predictive, and etiologically significant”.2
Observational studies show a benefit of lower BP down
to 115/75 for both men and women aged 40 to 89
years in relation to risk of first fatal or nonfatal stroke.3,4
Multiple randomized controlled trials have also shown
a benefit of moderate BP lowering in primary stroke
prevention, and some have shown a benefit of more

intensive BP lowering to various targets as well, but the
issue of what BP target is optimal for stroke prevention
remains unsettled.5
The SPRINT (Systolic Blood Pressure Intervention
Trial) randomized 9361 participants with an increased
cardiovascular risk, but without diabetes or a history of
stroke, to a systolic BP target of <120 mm Hg (intensive treatment) or a target of <140 mm Hg (standard
treatment) and was stopped early when the combined
primary end point was reached. The combined primary outcome favored the intensive BP arm, with significantly fewer fatal and nonfatal major cardiovascular
events (including stroke) and death from any cause.
However, although fewer strokes occurred in the intensive arm, only 147 stroke events had accrued by study

Correspondence to: Clinton B. Wright, 6001 Executive Blvd, Rockville, MD 20852. Email wright.clinton@gmail.com
For Sources of Funding and Disclosures, see page 1397.
© 2021 American Heart Association, Inc.
Hypertension is available at www.ahajournals.org/journal/hyp

Hypertension. 2021;77:1391–1398. DOI: 10.1161/HYPERTENSIONAHA.120.16027

April 2021   1391

Wright et al

SPRINT: Intensive BP Control and Stroke Subtypes

SPRINT

Novelty and Significance
What Is New?
• SPRINT (Systolic Blood Pressure Intervention Trial)
provided a unique opportunity to compare intensive
blood pressure control to standard blood pressure control in relation to the risk of hemorrhagic and ischemic
stroke and their subtypes.

What Is Relevant?
• Hypertension is a strong risk factor for stroke through
its effects on the heart and systemic arteries.
• Intensive blood pressure lowering could halt the deleterious effects of hypertension and lower the risk of

Nonstandard Abbreviation and Acronyms
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ACCORD	Action to Control Cardiovascular Risk in
Diabetes
BP
blood pressure
CCS
Causative Classification System
CE
cardiac embolism
HOPE
Heart Outcomes Prevention Evaluation
SPRINT
Systolic Blood Pressure Intervention Trial
SPS3	Secondary Prevention of Small Subcortical Strokes

termination.6 Since stroke is a broad term referring to
events caused by multiple mechanisms, most of them
modifiable by treatment of hypertension, it is important
to examine the effect of intensive BP lowering on different stroke subtypes to better understand the mechanisms that link hypertension with different types of brain
damage. BP-lowering appears to be beneficial for preventing both ischemic and hemorrhagic stroke, but only
limited data are available on the effects of BP treatment
on different types of stroke, especially ischemic stroke
subtypes.3,4 Cerebral small vessel disease due to hypertensive vasculopathy can manifest as small subcortical
(ie, lacunar) infarctions and intraparenchymal hemorrhages and may be the most direct link between high
BP and stroke. Hypertension also leads to heart disease,
including myocardial infarction, nonvalvular atrial fibrillation, and heart failure predisposing to cardiac embolism
(CE) that results in stroke. Large vessel atherosclerosis
leads to local thrombosis or artery to artery embolism.
Given the established links between hypertension and
small vessel stroke, and the reductions in heart failure
and cardiovascular mortality due to intensive BP lowering seen in SPRINT, we hypothesized that intensive BP
lowering would also result in fewer strokes attributable
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stroke or cause brain ischemia in the setting of longstanding hypertension.

Summary
The number of hemorrhagic and ischemic stroke subtypes were similar across the intensive and standard
blood pressure arms of SPRINT. Intensive blood pressure lowering was not associated with an elevated risk
of cerebral small vessel strokes compared with standard control.

to cerebral small vessel disease or those attributable to
a cardiogenic mechanism.

METHODS
The data that support the findings of this study are available
from the corresponding author upon reasonable request.

Study Design
Stroke subtyping was a prespecified outcome. The design
and cardiovascular outcome results for SPRINT have been
described previously.6,7 Adults 50 years of age or older with
systolic BP between 130 and 180 mm Hg at screening were
enrolled. Participants were at elevated cardiovascular risk,
defined as either having chronic kidney disease with an estimated glomerular filtration rate of 20 to <60 mL/(min·1.73
m2), a 10-year Framingham cardiovascular disease risk ≥15%,
or being 75 years of age or older. Exclusions included having
diabetes, a history of prior stroke or dementia, or living in a
nursing home. Enrolled participants were randomly assigned to
either an intensive treatment strategy with a systolic BP goal of
<120 mm Hg or a standard treatment strategy with a systolic
BP goal of <140 mm Hg. SPRINT was funded by the National
Heart, Lung, and Blood Institute and co-funded by the National
Institute of Diabetes and Digestive and Kidney Diseases, the
National Institute of Neurological Disorders and Stroke, and the
National Institute on Aging. An independent data and safety
monitoring board monitored unblinded trial results and safety
events. The study was approved by the institutional review
board at each participating study site (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062).

Stroke Adjudication and Subtyping
Randomization was stratified by clinical site and participants,
and study personnel were aware of study-group assignments,
but outcome adjudicators were blinded and did not adjudicate
cases from their home networks. Medical records and electrocardiograms were obtained for documentation of events
and whenever clinical site staff became aware of a stroke, the
approved protocol was followed to obtain information on the
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We compared the number of participants with stroke types
and subtypes across treatment arms using χ2 tests or Fisher
exact tests (for expected cell counts <5). The 3 major stroke
types were hemorrhagic, ischemic, and unknown. Hemorrhagic
strokes were classified as subarachnoid, intraparenchymal, or
other. We then used Cox proportional hazard models stratified
by clinical site to estimate hazard ratios and 95% CIs comparing stroke rates across prespecified subgroups using tests
of interaction with significance defined as Hommel-adjusted
alpha levels smaller than 0.05.12

RESULTS
Characteristics of the SPRINT participants are shown
in Table 1 and were well balanced across BP treatment
arms. Of 9361 participants randomized to intensive
(N=4678) or standard (N=4683) BP control, 69 participants in the intensive arm versus 78 participants in
the standard arm had strokes during a mean followup of 3.33 years (Figure 1). There was no significant
difference in the number of strokes overall by treatment arm.6 Likewise, baseline cardiovascular risk factor status did not significantly modify the effect of the
intervention. However, for those having no prior history
of cardiovascular disease at baseline, results favored
intensive BP control, but this did not reach significance
(P=0.05, Figure 2).
Hemorrhagic and ischemic strokes and their subtypes
across treatment arms are shown in Table 2. There were
32 events that could not be classified as to type, and 5
with incomplete stroke evaluations that prevented subtype classification. Roughly 70% of strokes were ischemic, with cryptogenic (31%) and cardioembolic (25%)
being the most common subtypes. The treatment effects

of intensive BP were consistent for the different stroke
subtypes with generally fewer strokes in the intensive
arm regardless of subtype. Likewise, treatment effects
were similar across arms when the undetermined category was broken into subgroups, when the CE category
was stratified into major and minor, and when minor CE
was combined with the cryptogenic category. The number of ischemic and hemorrhagic stroke subtypes was
similar across age (<75 versus ≥75 years), sex, and
race/ethnic strata (P=0.05, Figure 2).

DISCUSSION
In this prespecified analysis of SPRINT data, intensive
BP lowering resulted in similar numbers, types, and subtypes of strokes compared with standard BP control during follow-up. The numbers of hemorrhagic and ischemic
stroke subtypes were similar across arms.
As indicated in the primary outcomes report, intensive
BP control in SPRINT participants reduced the risk of
heart failure and death from cardiovascular causes, with
a nonsignificant decrease in the number of myocardial
infarctions as well.6 Given these findings, a lower risk
of ischemic strokes caused by CE in the intensive BP
control group than the standard control group might be
expected. However, the number of stroke events was
small, and SPRINT was not powered to detect these
differences. Although the anticipated difference in systolic BP between randomized arms (>10 mm Hg) was
achieved, it is possible a difference in strokes may have
been observed if greater systolic BP differences across
arms had been attained.
Hypertension is a major risk factor for small vessel
arteriopathies that lead to end-organ damage affecting
the brain, heart, kidney, and eye.13–16 Intensive BP lowering could limit such damage in patients with hypertension, thereby protecting against stroke. In the SPS3
(Secondary Prevention of Small Subcortical Strokes) trial
that enrolled participants with recent lacunar strokes
who were thus at greater risk of stroke than those in
SPRINT, maintaining systolic BP below 130 mm Hg
compared with 130 to 139 mm Hg resulted in significantly fewer incident intraparenchymal hemorrhages
but not new ischemic strokes.17 Since intraparenchymal
hemorrhage often results in severe morbidity and mortality, it is notable that intensive BP lowering did not result
in fewer hemorrhages compared with standard control in
the current study.
Intensive lowering of BP in patients with longstanding
hypertension could also place some organs at risk of ischemia should BP be lowered too aggressively. In the brain,
longstanding hypertension has been hypothesized to
require greater BPs to maintain adequate cerebral perfusion pressures and avoid ischemia due to a rightward shift
in the autoregulatory curve.18 Data are limited, but a small
study showed cerebral hemodynamic responses were
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event.7 A member of the Stroke Subcommittee (C. Wright) of
the Morbidity and Mortality Committee of SPRINT adjudicated
stroke subtypes using the Causative Classification System
(CCS), a standardized, automated, evidence-based, and webbased subtype classification system adapted for use in SPRINT
as specified in the design and rationale publication.7,8 The CCS
generated 5 mutually exclusive categories for each case: large
artery atherosclerosis (supra-aortic), CE, small artery occlusion,
other uncommon causes, and undetermined causes.8–10 The
undetermined category was further divided into cryptogenic,
multiple competing causes, and incomplete evaluation.8,9 We
also stratified CE into major-CE and minor-CE where major CE
denotes cardio-embolic sources with high potential to cause a
stroke such as atrial fibrillation, and minor CE indicates sources
with a low- or uncertain potential to cause a stroke such as
mitral annulus calcification (1–4).8–11 Finally, we generated an
additional cryptogenic group that also included low- or uncertain-risk cardiac sources. The CCS software stratified each
CCS category into 3 confidence levels as evident, probable, and
possible depending on the level of causal evidence. Because of
the small number of strokes, we determined the effects of the
intervention by aggregating the confidence levels.

SPRINT: Intensive BP Control and Stroke Subtypes

Wright et al

SPRINT: Intensive BP Control and Stroke Subtypes

Table 1. Baseline Clinical Characteristics by Treatment Arm
Intensive treatment (N=4678)

SPRINT

Characteristic

Standard treatment (N=4683)

Criterion for increased cardiovascular risk, n (%)

Table 1.

Continued

Characteristic

Intensive treatment (N=4678)

Standard treatment (N=4683)

Framingham 10-y CVD risk score, %

24.8±12.6

24.8±12.5

Age ≥75 y

1317 (28.2%)

1319 (28.2%)

Body mass index

29.9±5.8

29.8±5.7

Chronic kidney disease

1329 (28.5%)

1316 (28.3%)

Antihypertensive medications prescribed, no/patient

1.8±1.0

1.8±1.0

Not using antihypertensive agents,
n (%)

432 (9.2%)

450 (9.6%)

Cardiovascular disease, n (%)

940 (20.1%)

937 (20.0%)

Clinical

779 (16.7%)

783 (16.7%)

Subclinical

247 (5.28%)

246 (5.3%)

Framingham 10-y cardiovascular
disease risk score ≥15%

3556 (76.0%)

3547 (75.7%)

1684 (36.0%)

1648 (35.2%)

Overall

67.9±9.4

67.9±9.5

Among those ≥75 y of age

79.8±3.9

79.9±4.1

Non-Hispanic Black

1379 (29.5%)

1423 (30.4%)

Hispanic

503 (10.8%)

481 (10.3%)

Non-Hispanic White

2698 (57.7%)

2701 (57.7%)

Other

98 (2.1%)

78 (1.7%)

1454 (31.1%)

1493 (31.9%)

Systolic

139.7±15.8

139.7±15.4

Diastolic

78.2±11.9

78.0±12.0

Female sex, n (%)
Age, y

Race or ethnic group, n (%)

Black race*
Baseline blood pressure, mm Hg

Distribution of systolic blood pressure, n (%)
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≤132 mm Hg

1583 (33.8%)

1553 (33.2%)

>132 to <145 mm Hg

1489 (31.8%)

1549 (33.1%)

≥145 mm Hg

1606 (34.3%)

1581 (33.8%)

1.07±0.34

1.08±0.34

Serum creatinine, mg/dL
Estimated GFR, mL/(min·1.73 m )
2

Among all participants

71.8±20.7

71.7±20.5

Among those with estimated GFR
≥60 mL/(min·1.73 m2)

81.3±15.5

81.1±15.5

Among those with estimated GFR
<60 mL/(min·1.73 m2)

47.8±9.5

47.9±9.5

Ratio of urinary albumin (mg) to creatinine (g)

44.1±178.7

41.1±152.9

Fasting total cholesterol, mg/dL

190.2±41.4

190.0±40.9

Fasting HDL cholesterol, mg/dL

52.9±14.3

52.8±14.6

Fasting total triglycerides, mg/dL

124.8±85.8

127.1±95.0

Fasting plasma glucose, mg/dL

98.8±13.7

98.8±13.4

Statin use, n/total n (%)

1978/4646
(42.6%)†

2076/4640
(44.7%)†

Aspirin use, n/total n (%)

2406/4662
(51.6%)†

2350/4666
(50.4%)†

Never smoked

2051 (43.8%)

2072 (44.2%)

Former smoker

1977 (42.3%)

1996 (42.6%)

Current smoker

639 (13.7%)

601 (12.8%)

Missing data

11 (0.2%)

14 (0.3%)

390/4661
(8.4%)†

364/4666
(7.8%)†

Smoking status, n (%)

Atrial fibrillation, n/total n (%)

(Continued )

1394   April 2021

CVD indicates cardiovascular disease; HDL, high density lipoprotein; and GFR,
glomerular filtration rate. Black race includes Hispanic Black and Black as part of
a multiracial identification.
Black race includes Hispanic Black and Black as part of a multiracial identification.
†Denominator smaller than overall treatment arm totals due to missing data.

stable acutely and up to four months later after initiating
treatment of mild and moderate hypertension.19 In SPRINT,
intensive BP lowering also did not increase the risk of
stroke subtypes usually attributable to cerebral small vessel disease such as intracerebral hemorrhage and lacunar
stroke. These findings are consistent with the ACCORD
trial (Action to Control Cardiovascular Risk in Diabetes)
where intensive BP control targeted below 130 mm Hg
significantly lowered stroke risk and with pooled data from
SPRINT and ACCORD that showed no increase in stroke
risk from intensive BP lowering.20,21 Further, the SPRINT
MIND study found intensive BP control lowered the risk of
mild cognitive impairment and the combined outcome of
mild cognitive impairment and probable dementia.22 Intensive BP control did not prevent probable dementia alone
(the primary outcome) compared with standard BP control, but there were only about half as many dementia as
mild cognitive impairment events due to early termination.
In the current study, we did not find a notable difference
between treatment arms in the number of hemorrhagic
or ischemic strokes usually attributed to small vessel
arteriopathies, namely intraparenchymal hemorrhages
and lacunar infarctions. However, the SPRINT-MIND
MRI sub-study showed that participants in the intensive
BP treatment arm had less progression of white matter
hyperintensities than those in the standard arm and that
this effect did not differ across various subgroups (those
with and without prior cardiovascular disease; those with
and without a history of orthostatic hypertension; those
older versus younger than 75; and across baseline BP
levels).23 Since there was reason to be concerned about
the possible detrimental effects of intensive BP control
in all of these subgroups, these findings are reassuring. In addition, since only 22 strokes in the small vessel subtype categories occurred during follow-up, lack of
concordance with the MRI sub-study findings could be
attributable to the small number of events. In addition,
white matter hyperintensities are areas of extracellular
water detected on T2-weighted MRI sequences and,
though strongly associated with small vessel damage,
are nonspecific.
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Figure 1. Cumulative incidence plot of stroke events by treatment arm in SPRINT (Systolic Blood Pressure Intervention Trial).
The cumulative incidence of stroke events (y axis) in each SPRINT study arm is plotted for the number of participants at risk by month of followup (x axis).
Downloaded from http://ahajournals.org by on March 11, 2021

SPRINT was not designed to examine hypertensive
medication class effects, and the small number of ischemic strokes does not allow for a meaningful analysis

of the potential class effects of different BP agents.
Some classes have been posited to provide additional
benefits beyond BP lowering. For example, the HOPE

Figure 2. Forest plot of stroke outcome by subgroups.
The forest plot for the groups of interest. Note that all interactions between covariate and treatment arm are nonsignificant for stroke as an
outcome at the <0.05 significance level. CKD, chronic kidney disease; CVD, cardiovascular disease; and SBP, systolic blood pressure.
Hypertension. 2021;77:1391–1398. DOI: 10.1161/HYPERTENSIONAHA.120.16027
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Table 2.

Stroke Subtypes in the SPRINT

Stroke Outcome

Overall (N=9361)

Intensive (N=4678)

Standard (N=4683)

P value

Absolute overall, n (%)

147 (1.6)

69 (1.5)

78 (1.7)

0.51

Hemorrhagic stroke, n (%)

13 (0.1)

6 (0.1)

7 (0.2)

1.00

Subarachnoid hemorrhage

3 (0.0)

2 (0.0)

1 (0.0)

0.65*

Intraparenchymal hemorrhage

6 (0.1)

3 (0.1)

3 (0.1)

1.00*

Other hemorrhage
Ischemic stroke, n (%)
Large artery atherosclerosis
Cardiac embolism

4 (0.0)

1 (0.0)

3 (0.1)

0.62*

102 (1.1)

48 (1.0)

54 (1.2)

0.62

24 (0.3)

11 (0.2)

13 (0.3)

0.84

26 (0.3)

11 (0.2)

15 (0.3)

0.56

   Major cardiac embolism

13 (0.1)

5 (0.1)

8 (0.2)

0.58

   Minor cardiac embolism

13 (0.1)

6 (0.1)

7 (0.2)

1.00

Small artery occlusion

16 (0.2)

8 (0.2)

8 (0.2)

1.00

Other uncommon causes

4 (0.0)

3 (0.1)

1 (0.0)

0.38*

Undetermined cause
   Unknown: cryptogenic embolism

32 (0.3)

15 (0.3)

17 (0.4)

0.86

19 (0.2)

8 (0.2)

11 (0.2)

0.65

   Multiple competing causes

8 (0.1)

4 (0.1)

4 (0.1)

1.00*

  Incomplete evaluation

5 (0.1)

3 (0.1)

2 (0.0)

0.69*

Unknown stroke type, n (%)

32 (0.3)

15 (0.3)

17 (0.4)

0.86

SPRINT indicates Systolic Blood Pressure Intervention Trial.
*Denotes Fisher exact test.
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trial (Heart Outcomes Prevention Evaluation) showed a
benefit to adding ramipril to standard BP treatment for
both ischemic and hemorrhagic stroke, and the Systolic
Hypertension in the Elderly Program showed a benefit of chlorthalidone versus placebo for various stroke
subtypes.24,25
The CCS was used for ischemic stroke subtype classification in this study and differs from conventional systems in that it is fully rule- and evidence-based as an
algorithm, using objective criteria to assign stroke causes
into easily replicable subtypes.26 The reported κ values
for CCS range between 0.75 and 0.90 depending on the
data source, number of cases, and number of raters.8–11
In contrast, reports from independent investigators demonstrate only moderate reliability with κ values ranging
between 0.42 and 0.54 for conventional etiologic classification systems.27–31 Likewise, CCS provides higher
discriminative validity compared with other classification
systems, because the CCS generates more distinct subtypes with discrete clinical, genetic, and prognostic features.26,32 However, the ability of etiologic classification,
regardless of the system used, to unambiguously assign
the cause of stroke is limited because of the absence of
pathology data. This problem is greater for the category
of CE as this category includes several abnormalities
with discrete embolic potential. The CCS provided the
flexibility to examine the effect of intensive BP reduction
across a wide range of causes generated based on the
strength of causal evidence. For instance, we stratified
cardiac sources into high risk and low- or uncertain-risk
CE. Likewise, we generated a new cryptogenic category
that included low- or uncertain-risk cardiac pathologies.
1396   April 2021

We found that the intervention effect was similar across
such categories, suggesting that the etiologic mechanism of stroke is not a strong determinant of benefit
from intensive BP reduction, with the caveat noted above
about the small number of strokes in each category.

Limitations
This study was not powered to detect differences in
stroke subtypes. The generalizability of these findings
is limited to people with higher cardiovascular risk than
the general population due to the enrollment criteria that
excluded those with diabetes mellitus, prior stroke, and
nursing home residents. A single adjudicator did the
ischemic stroke subtype classifications using the CCS
system, and intrarater reliability was not measured during
the adjudication process.
In summary, we found similar numbers of stroke subtypes in the intensive BP control and standard control
arms of SPRINT.

Perspectives
Hypertension leads to stroke through heart disease, especially atrial cardiopathy and atrial fibrillation, as well as large
vessel atherosclerosis and small vessel arteriolosclerosis.
In addition, longstanding hypertension may place the brain
at elevated risk of ischemia if BP is treated aggressively. It
is important to understand if intensive BP control affects
the risk of certain types of stroke. In SPRINT, intensive BP
control did not reduce the risk of stroke overall, but the
study was stopped early and the number of strokes was
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